(271 days)
Not Found
No
The summary describes a standard defibrillator/monitor with features like manual and automated external defibrillation, pacing, ECG monitoring, and pulse oximetry. There is no mention of AI or ML in the intended use, device description, or any other section. The modification described is a change in battery technology.
Yes
The device performs therapeutic functions such as manual and automated external defibrillation, and noninvasive pacing, which are treatments for various cardiac conditions.
Yes
Explanation: The device description explicitly states features like "ECG monitoring (3-wire or 5-wire)" and "pulse oximetry," and the indications for use include "The pulse oximeter is indicated for use in any patient who is at risk of developing hypoxemia." These functions involve collecting and analyzing physiological data to assess a patient's condition, which aligns with the definition of a diagnostic device. While it also performs therapeutic functions (defibrillation, pacing), it clearly has diagnostic capabilities.
No
The device description clearly states it is a defibrillator/monitor with hardware components like AC power, internal battery, and capabilities for manual and automated external defibrillation, noninvasive pacing, ECG monitoring, and pulse oximetry. The modification described is a change in battery technology, which is a hardware change.
Based on the provided text, the LIFEPAK 20e defibrillator/monitor is not an IVD (In Vitro Diagnostic) device.
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- LIFEPAK 20e Function: The LIFEPAK 20e is a medical device that directly interacts with the patient's body through electrodes for defibrillation, pacing, and ECG monitoring, and through a sensor for pulse oximetry. It does not analyze samples taken from the body.
- Intended Use: The intended use describes direct patient care and intervention (defibrillation, pacing, monitoring vital signs).
- Device Description: The description focuses on the hardware and its functions related to direct patient interaction.
Therefore, the LIFEPAK 20e falls under the category of a therapeutic and monitoring medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The LIFEPAK 20e defibrillator/monitor is intended for use in the hospital, physician's office, and clinic setting by personnel who are authorized by a physician/medical director. It is intended for use on a "crash cart" as well as for portable emergency response throughout a hospital.
Manual Defibrillation:
Indications: Defibrillation is a recognized means of terminating certain fatal arrhythmias, such as ventricular fibrillation and symptomatic ventricular tachycardia. Delivery of this energy in the synchronized mode is a method for treating atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, and, in relatively stable patients, ventricular tachycardia.
Contraindications: Defibrillation is contraindicated in the treatment of Pulseless Electrical Activity (PEA) such as idioventricular escape rhythms, and in the treatment of asystole.
Automated External Defibrillation:
Indications: The AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patient's ECG rhythm.
Noninvasive Pacing
Indications: Noninvasive pacing is indicated for symptomatic bradycardia in patients with a pulse.
Contraindications: Noninvasive pacing is contraindicated for the treatment of ventricular fibrillation and asystole.
Pulse Oximetry
Indications: The pulse oximeter is indicated for use in any patient who is at risk of developing hypoxemia.
Product codes
MKJ
Device Description
The LIFEPAK 20 defibrillator/monitor was created especially for hospitals and clinics for use on "crash carts" as well as for portable emergency response throughout a hospital. The LIFEPAK 20 defibrillator/monitor is equipped with AC power and a backup internal battery. Features of the LIFEPAK 20 defibrillator/monitor include manual and automated external defibrillation, noninvasive pacing, ECG monitoring (3-wire or 5-wire), pulse oximetry, and synchronized cardioversion.
The LIFEPAK 20 defibrillator/monitor has been modified with new battery technology. This modification includes a change in the chemistry of the internal battery from nickel-metal hydride to lithium ion, and the addition of a battery status indicator on the device display indicating the approximate amount of operating time available while using battery power.
The model name of devices with this new battery technology is the LIFEPAK 20e defibrillator/monitor.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
The biphasic defibrillation waveform used in this device has only been clinically tested on adults; it has not been tested on pediatric patients.
In AED mode, the LIFEPAK 20e defibrillator/monitor is not intended for use on pediatric patients less than 8 years old.
Intended User / Care Setting
hospital, physician's office, and clinic setting by personnel who are authorized by a physician/medical director.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.5310 Automated external defibrillator system.
(a)
Identification. An automated external defibrillator (AED) system consists of an AED and those accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., battery, pad electrode, adapter, and hardware key for pediatric use). An AED system analyzes the patient's electrocardiogram, interprets the cardiac rhythm, and automatically delivers an electrical shock (fully automated AED), or advises the user to deliver the shock (semi-automated or shock advisory AED) to treat ventricular fibrillation or pulseless ventricular tachycardia.(b)
Classification. Class III (premarket approval)(c)
Date PMA or notice of completion of PDP is required. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED that was in commercial distribution before May 28, 1976. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976. Any other AED and AED accessory described in paragraph (a), shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
Physio-Control Inc. LIFEPAK 20e defibrillator/monitor 510(k) Premarket Notification
SECTION E - 510(k) SUMMARY
Submitter's Name and Address:
Physio-Control, Inc. 11811 Willows Road Northeast Redmond, WA 98052
JUL 2 9 2008
Contact Person:
Michelle Ackermann Principal Regulatory Affairs Specialist
Date Summary Prepared:
October 31, 2007
Device:
LIFEPAK® 20e defibrillator/monitor
Classification:
| Classification Name | Class |
|---|---|
| Low Energy DC-Defibrillator | II |
| Automatic External Defibrillator | III |
| Cardiac Monitor (Including Cardiotachometer & Rate Alarm) | II |
| Cardiac External Transcutaneous (Non-Invasive) | II |
| Pacemaker | II |
| Electrocardiograph | II |
| Hydraulic, Pneumatic, or Photoelectric Plethysmographs | II |
| Oximeter | II |
1
Substantial Equivalence:
The features and functions of the LIFEPAK 20e defibrillator/monitor are substantially equivalent to the previously cleared LIFEPAK 20 defibrillator/monitor (K063119, K033275, and K012274).
Description:
The LIFEPAK 20 defibrillator/monitor was created especially for hospitals and clinics for use on "crash carts" as well as for portable emergency response throughout a hospital. The LIFEPAK 20 defibrillator/monitor is equipped with AC power and a backup internal battery. Features of the LIFEPAK 20 defibrillator/monitor include manual and automated external defibrillation, noninvasive pacing, ECG monitoring (3-wire or 5-wire), pulse oximetry, and synchronized cardioversion.
The LIFEPAK 20 defibrillator/monitor has been modified with new battery technology. This modification includes a change in the chemistry of the internal battery from nickel-metal hydride to lithium ion, and the addition of a battery status indicator on the device display indicating the approximate amount of operating time available while using battery power.
The model name of devices with this new battery technology is the LIFEPAK 20e defibrillator/monitor.
Intended Use:
The LIFEPAK 20e defibrillator/monitor is intended for use in the hospital, physician's office, and clinic setting by personnel who are authorized by a physician/medical director. It is intended for use on a "crash cart" as well as for portable emergency response throughout a hospital.
Indications for Use:
Manual Defibrillation:
Indications: Defibrillation is a recognized means of terminating certain fatal arrhythmias, such as ventricular fibrillation and symptomatic ventricular tachycardia. Delivery of this energy in the synchronized mode is a method for treating atrial fibrillation, atrial flutter, paroxysmal
2
supraventricular tachycardia, and, in relatively stable patients, ventricular tachycardia.
The biphasic defibrillation waveform used in this device has only been clinically tested on adults; it has not been tested on pediatric patients.
Contraindications: Defibrillation is contraindicated in the treatment of Pulseless Electrical Activity (PEA) such as idioventricular escape rhythms, and in the treatment of asystole.
Automated External Defibrillation:
Indications: The AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patient's ECG rhythm. In AED mode, the LIFEPAK 20e defibrillator/monitor is not intended for use on pediatric patients less than 8 years old.
Noninvasive Pacing
Indications: Noninvasive pacing is indicated for symptomatic bradycardia in patients with a pulse.
Contraindications: Noninvasive pacing is contraindicated for the treatment of ventricular fibrillation and asystole.
Pulse Oximetry
Indications: The pulse oximeter is indicated for use in any patient who is at risk of developing hypoxemia.
Technological characteristics of new and predicate device:
The main difference between the LIFEPAK 20e defibrillator/monitor and the predicate LIFEPAK 20 defibrillator/monitor is new technology for the internal backup battery and the addition of a battery status indicator on the device display. Features of the LIFEPAK 20e defibrillator/monitor such as the ECG analysis system, defibrillation waveform, and noninvasive pacing are the same as those of the predicate device.
Defibrillation technology and functionality of the LIFEPAK 20e defibrillator/monitor have not changed from the previously cleared LIFEPAK 20 device.
3
Summary of Design Controls:
This 510(k) includes a summary of design control activities and a declaration of conformity to design controls.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.
The information in this 510(k) notification demonstrates that the LIFEPAK 20e defibrillator/monitor is substantially equivalent to the predicate LIFEPAK 20 device.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird with outstretched wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird symbol.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
29
Physio-Control, Inc. c/o Ms. Michelle Ackermann 11811 Willows Rd., N.E. PO Box 97006 Redmond, WA 98052
Re: K073089
Trade/Device Name: LIFEPAK 20e Defibrillator/Monitor Regulation Number: 21 CFR 850.5310 Regulation Name: Automated external defibrillator Regulatory Class: Class III Product Code: MKJ Dated: July 8, 2008 Received: July 10, 2008
Dear Ms. Ackermann:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807);
5
Page 2 - Ms. Michelle Ackermann
labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-3464. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure
6
SECTION D - STATEMENT OF INDICATIONS FOR USE
510(k) Number (if known): not yet assigned
Device Name: LIFEPAK 20e defibrillator/monitor
Indications For Use:
Manual Defibrillation:
Indications: Defibrillation is a recognized means of terminating certain fatal arrhythmias, such as ventricular fibrillation and symptomatic ventricular tachycardia. Delivery of this energy in the synchronized mode is a method for treating atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, and, in relatively stable patients, ventricular tachycardia.
The biphasic defibrillation waveform used in this device has only been clinically tested on adults; it has not been tested on pediatric patients.
Contraindications: Defibrillation is contraindicated in the treatment of Pulseless Electrical Activity (PEA) such as idioventricular escape rhythms, and in the treatment of asystole.
Automated External Defibrillation:
Indications: The AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patient's ECG rhythm. In AED mode, the LIFEPAK 20e defibrillator/monitor is not intended for use on pediatric patients less than 8 years old.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use_ (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDR e Evaluation (ODE)
Page 1 of 2
(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K073069
7
SECTION D - STATEMENT OF INDICATIONS FOR USE
510(k) Number (if known): not yet assigned
Device Name: LIFEPAK 20e defibrillator/monitor
Indications For Use:
Noninvasive Pacing
Indications: Noninvasive pacing is indicated for symptomatic bradycardia in patients with a pulse.
Contraindications: Noninvasive pacing is contraindicated for the treatment of ventricular fibrillation and asystole.
Pulse Oximetry
Indications: The pulse oximeter is indicated for use in any patient who is at risk of developing hypoxemia.
Prescription Use _ (Part 21 CFR 801 Subpart D)
Page 2 of
. :
AND/OR
Over-The-Counter Use _ (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
|--|--|
of 2
| (Division Sign-Off |
|---|
| Division of Cardiovascular Devices |
510(k) Number_Ko73089
D-2